# DSIP Research: EEG, HPA Axis, and Insomnia Studies, Logged > DSIP research logged study by study: the 1977 EEG discovery, 1980s human insomnia trials, HPA-axis and growth-hormone findings, the 2024 fusion peptide, and the gaps. The discovery, the human insomnia trials, the neuroendocrine work, the 2024 fusion peptide, and the unresolved mechanism, each with its source. ## The short version DSIP research starts with one clean finding and gets murkier from there. In 1977, scientists pulled a nine-amino-acid peptide from the blood of sleeping rabbits and showed it boosted the slow brain waves of deep sleep [1]. In the 1980s, a small group of European researchers gave it to people with long-term insomnia and reported better sleep, though the effect was modest [2][7]. Other studies looked at whether DSIP changes stress hormones [4], growth hormone, or melatonin [13], and a 2003 mouse study even linked a DSIP preparation to a longer lifespan [5]. A 2024 study built an improved, brain-penetrating version that worked better than the original in mice [6]. The catch runs through all of it: no one has found the receptor DSIP acts on, and several human studies could not reproduce its effects [3]. This page logs each major study and marks where the record has gaps. ## The discovery: a delta sleep inducing peptide DSIP entered the literature in 1977, when Schoenenberger and Monnier characterized it as a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that, infused into the brain, produced significant and specific enhancement of delta and spindle EEG activity, the electrical hallmarks of deep, non-REM sleep [1]. The name encodes that result: a delta sleep inducing peptide. The discovery method is part of why the molecule has always been hard to pin down, it was identified by an effect (delta-wave enhancement in a sleep assay) rather than by binding to a known target. Later rodent work added detail: in freely moving rats, central or peripheral delta-sleep peptide produced a phasic shift in brain electrical activity and a significant increase in delta waves in the putamen, with structural analogs producing related EEG spectral shifts [12]. The signature effect is therefore reproducible in animals, even as its cause stays unidentified. ## The human insomnia trials The most consequential human work on DSIP was a cluster of European studies, largely from one investigator, in the 1980s and early 1990s. Acute intravenous DSIP at 25 nmol/kg improved disturbed sleep in six middle-aged chronic insomniacs, producing longer duration, fewer interruptions, slightly more REM, and no daytime sedation, with the sleep-promoting effect emerging in the second hour after injection [2]. In severe chronic insomnia, DSIP improved sleep efficiency and duration with significant gains in daytime alertness and performance that carried into the first post-treatment night [8]. A 10-injection course reportedly normalized sleep in six of seven patients with durable benefit over a 3-7 month follow-up [9], and separate work reported normalization across both middle-aged and elderly insomniacs, with the treatment effect related to baseline severity [10]. DSIP was even used to correct phase-shifted insomnia, reportedly advancing the sleep phase by roughly five hours and enabling complete withdrawal from a benzodiazepine hypnotic [11]. The crucial qualifier came from the most rigorous of these: a double-blind study confirmed higher sleep efficiency and shorter latency versus placebo, but characterized the effects as modest and concluded short-term treatment alone was unlikely to be of major therapeutic benefit [7]. ## The stress, hormone, and pineal findings Beyond sleep, DSIP was tested for neuroendocrine effects, with results that often failed to replicate across species. In men, intravenous DSIP at 25 nmol/kg significantly reduced plasma ACTH-like immunoreactivity for at least three hours while cortisol was unaffected and followed its normal diurnal decline [4], suggesting a selective action on the stress (HPA) axis, the system that governs cortisol release. Supporting an HPA link, immunoreactive DSIP in the rat was co-localized with TSH in the pituitary and with noradrenaline in the adrenal medulla, and bilateral adrenalectomy significantly raised plasma DSIP [15]. In cultured rat pineal glands, DSIP increased serotonin N-acetyltransferase activity, a rate-limiting step in melatonin synthesis, and enhanced norepinephrine's stimulatory effect on that enzyme [13], hinting at a route to the sleep hormone melatonin. A separate review addressed DSIP's proposed anti-stress effects [14]. The honest caveat: an early human ACTH-lowering finding was not reproduced in later human HPA work, and rat growth-hormone effects did not carry over to human studies in women, a recurring cross-species non-replication that defines this part of the record. ## Longevity, the 2024 fusion peptide, and recent data Two findings sit at the frontier of DSIP research. First, longevity: monthly courses of the DSIP-containing preparation Deltaran (~100 micrograms/kg, five consecutive days per month) in female SHR mice increased maximum lifespan by 24.1%, extended the last 10% of survivors' lifespan by 17.1%, reduced total spontaneous tumor incidence 2.6-fold, and reduced bone-marrow chromosome aberrations by 22.6% [5]. These are large effects, but the geroprotector data comes from a small set of related research groups and needs independent replication before any strong claim. Second, bioengineering: a 2024 study built a DSIP fusion peptide engineered to cross the blood-brain barrier (DSIP-CBBBP), which reduced average daily wakefulness from roughly 720 to 500 minutes (~31%) in PCPA-induced insomnia mice, restored melatonin, serotonin, and dopamine, produced anxiolytic and antidepressant effects, increased hippocampal neuron density, and outperformed unmodified DSIP [6]. The 2024 work is notable because it suggests the native peptide's inconsistency may owe partly to poor brain delivery, a hypothesis, not a settled conclusion. ## The logged gaps: receptor, replication, and the missing RCT The defining feature of the DSIP literature is logged absence. Despite decades of work, no specific DSIP receptor, gene, or precursor protein has been conclusively isolated, leaving the mechanism unresolved [3]. The signature sleep effect has been inconsistently replicated; the 2006 Journal of Neurochemistry review concluded the sleep-promotion hypothesis is extremely poorly documented and still weak, and noted that synthetic analogs, not native DSIP, often drove the clearest effects [3]. There is no large randomized controlled trial, no validated human pharmacokinetics, and no regulatory approval for any indication. DSIP also shows a reported parabolic dose-response, meaning higher doses are not reliably more effective than intermediate ones, which complicates every interpretation. These gaps are not a footnote to the DSIP story; they are the center of it, and any reading of the positive findings has to be held against them. --- A logged reading of the DSIP literature, gaps included; not a clinic, not a vendor, not medical advice.